- Home
- VCEL vs IMTX Comparison
VCEL vs IMTX Comparison
Compare VCEL & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VCEL | IMTX |
|---|---|---|
| Founded | 1989 | N/A |
| Country | United States | Germany |
| Employees | N/A | 423 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | VCEL | IMTX |
|---|---|---|
| Price | $32.58 | $9.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $58.50 | $19.25 |
| AVG Volume (30 Days) | 468.7K | ★ 469.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.00 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $276,259,000.00 | N/A |
| Revenue This Year | $19.09 | $1.92 |
| Revenue Next Year | $17.96 | $15.88 |
| P/E Ratio | $101.67 | ★ N/A |
| Revenue Growth | ★ 16.45 | N/A |
| 52 Week Low | $29.24 | $3.30 |
| 52 Week High | $48.75 | $12.41 |
Technical Indicators
Market Signals| Indicator | VCEL | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.26 | 47.75 |
| Support Level | $31.34 | $9.61 |
| Resistance Level | $38.48 | $10.83 |
| Average True Range (ATR) | 1.42 | 0.60 |
| MACD | -0.31 | -0.07 |
| Stochastic Oscillator | 20.52 | 40.13 |
Price Performance
Historical ComparisonAbout VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.